A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687 on ClinicalTrials.gov · last registry update 2015-01-26

An unusually large phase 3: 978 participants, more than double the 424 typical for the stage. The sponsor logged completion for November 2011. Primary outcome, as filed: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c). dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 978
Started: 2010-02
Primary completion: 2011-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.